Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $1.7 million.

  • Century Therapeutics' Non Operating Income fell 5212.38% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 3368.91%. This contributed to the annual value of $13.4 million for FY2024, which is 1367.19% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Non Operating Income is $1.7 million, which was down 5212.38% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Non Operating Income registered a high of $3.6 million during Q2 2024, and its lowest value of -$61000.0 during Q1 2022.
  • Moreover, its 4-year median value for Non Operating Income was $2.4 million (2025), whereas its average is $2.3 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first surged by 341967.21% in 2023, then tumbled by 5212.38% in 2025.
  • Over the past 4 years, Century Therapeutics' Non Operating Income (Quarter) stood at $1.7 million in 2022, then soared by 111.05% to $3.5 million in 2023, then dropped by 14.54% to $3.0 million in 2024, then tumbled by 43.02% to $1.7 million in 2025.
  • Its Non Operating Income stands at $1.7 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.4 million for Q1 2025.